Literature DB >> 10661679

Enhanced expression of interleukin-6 in chronic hepatitis C.

Y Oyanagi1, T Takahashi, S Matsui, S Takahashi, S Boku, K Takahashi, K Furukawa, F Arai, H Asakura.   

Abstract

AIMS/
BACKGROUND: There is a possibility that proinflammatory cytokines such as interleukin-6 (IL-6) are involved in the inflammatory process of chronic hepatitis C. This study was undertaken to investigate the possible role of IL-6 in the pathophysiology of chronic hepatitis C.
METHODS: Serum IL-6 levels in 63 patients with chronic hepatitis C and in 26 normal controls were measured. Light and electron immunostaining studies to localize IL-6 protein as well as in situ hybridization to localize IL-6 messenger RNA were performed on 10 liver biopsy specimens.
RESULTS: Serum IL-6 levels were significantly (p<0.01) elevated in chronic hepatitis C compared to those in normal controls. Although no statistically significant correlation was found between serum IL-6 levels and hepatobiliary enzyme levels, a significant correlation (p<0.01) was found between serum IL-6 levels and category II of Knodell's histological activity index score. Non-parenchymal cells in hepatic sinusoids and the cells infiltrating enlarged fibrous portal tracts were definitely positive for IL-6 protein and mRNA by immunohistochemistry and in situ hybridization. In addition, immunoelectron microscopy revealed a weak and occasional positive reaction in the cytoplasm of hepatocytes. The majority of the positive cells in hepatic sinusoids showed CD68 immunoreactivity in consecutive sections indicating that these were Kupffer cells. Sinusoidal endothelial cells and hepatic stellate cells also exhibited a weak reaction.
CONCLUSION: These results strongly suggest that Kupffer cells in liver parenchyma and macrophages infiltrating in portal tracts are the main producers of elevated IL-6 in serum. Moreover, there is a possibility that IL-6 produced by hepatocytes could also act as a regenerative stimulus to hepatocytes themselves in an autocrine fashion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10661679     DOI: 10.1111/j.1478-3231.1999.tb00078.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  18 in total

1.  Chronic pain and hepatitis C virus infection in opioid dependent injection drug users.

Authors:  Judith I Tsui; Debra S Herman; Malyna Kettavong; Bradley J Anderson; Michael D Stein
Journal:  J Addict Dis       Date:  2011-04

2.  Association of IL-6 polymorphisms with hepatocellular carcinoma risk: evidences from a meta-analysis.

Authors:  Ying Liu; Su-jun Gao; Bo-xiang Du; Jie-jun Wang
Journal:  Tumour Biol       Date:  2013-12-08

3.  Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation.

Authors:  Vijay Subramanian; Anil B Seetharam; Neeta Vachharajani; Venkataswarup Tiriveedhi; Nataraju Angaswamy; Sabarinathan Ramachandran; Jeffrey S Crippin; Surendra Shenoy; William C Chapman; Thalachallour Mohanakumar; Christopher D Anderson
Journal:  Transplantation       Date:  2011-12-15       Impact factor: 4.939

4.  Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders.

Authors:  Judith I Tsui; Marlene C Lira; Debbie M Cheng; Michael R Winter; Daniel P Alford; Jane M Liebschutz; Jianren Mao; Robert R Edwards; Jeffrey H Samet
Journal:  Drug Alcohol Depend       Date:  2015-05-22       Impact factor: 4.492

5.  Characterization of HCV-specific CD4+Th17 immunity in recurrent hepatitis C-induced liver allograft fibrosis.

Authors:  H I Basha; V Subramanian; A Seetharam; D S Nath; S Ramachandran; C D Anderson; S Shenoy; W C Chapman; J S Crippin; T Mohanakumar
Journal:  Am J Transplant       Date:  2011-04       Impact factor: 8.086

6.  Hepatitis C virus induces interleukin-1β (IL-1β)/IL-18 in circulatory and resident liver macrophages.

Authors:  Shubham Shrivastava; Anupam Mukherjee; Ranjit Ray; Ratna B Ray
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

7.  Immune response to extracellular matrix collagen in chronic hepatitis C-induced liver fibrosis.

Authors:  Brian B Borg; Anil Seetharam; Vijay Subramanian; Haseeb Ilias Basha; Mauricio Lisker-Melman; Kevin Korenblat; Christopher D Anderson; Surendra Shenoy; William C Chapman; Jeffrey S Crippin; Thalachallour Mohanakumar
Journal:  Liver Transpl       Date:  2011-07       Impact factor: 5.799

8.  Efficacy of MK615 for the treatment of patients with liver disorders.

Authors:  Atsushi Hokari; Tomohisa Ishikawa; Hisao Tajiri; Takahide Matsuda; Osamu Ishii; Nobuyuki Matsumoto; Chiaki Okuse; Hideaki Takahashi; Takeshi Kurihara; Ko-Ichi Kawahara; Ikuro Maruyama; Mikio Zeniya
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

9.  Effect of oophorectomy and exogenous estrogen replacement on liver injury in experimental obstructive jaundice.

Authors:  Hamdi Bulent Ucan; Mehmet Kaplan; Bulent Salman; Utku Yilmaz; B-Bulent Mentes; Cemalettin Aybay
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

10.  Macrophage interleukin-6 and tumour necrosis factor-alpha are induced by coronavirus fixation to Toll-like receptor 2/heparan sulphate receptors but not carcinoembryonic cell adhesion antigen 1a.

Authors:  Alexandre Jacques; Christian Bleau; Claire Turbide; Nicole Beauchemin; Lucie Lamontagne
Journal:  Immunology       Date:  2009-08-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.